Terms: = Breast cancer AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Prognosis
135 results:
1. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
2. Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
Hou X; Li X; Han Y; Xu H; Xie Y; Zhou T; Xue T; Qian X; Li J; Wang HC; Yan J; Guo X; Liu Y; Liu J
Cancer; 2024 Apr; 130(S8):1499-1512. PubMed ID: 38422056
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value and distribution pattern of tumor infiltrating lymphocytes and their subsets in distant metastases of advanced breast cancer.
Sun XY; Wang CQ; Mao Y; Zhang ZQ; Cui J; Dong XN; Wang HB
Clin Breast Cancer; 2024 Apr; 24(3):e167-e176. PubMed ID: 38212189
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA; Decker T; Hartkopf A; Nusch A; Heinrich BJ; Kurbacher C; Fuchs R; Tesch H; Krabisch P; Huober J; Kuemmel S; Brucker S; Janni W; Schneeweiss A; Schuler M; Fehm T; Lüftner D; Quiering C; Voges C; Kreuzeder J; Reinisch M
Eur J Cancer; 2024 Feb; 198():113480. PubMed ID: 38154393
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination Treatment for Triple-Negative breast cancer.
Chu SL
Stud Health Technol Inform; 2023 Nov; 308():341-350. PubMed ID: 38007758
[TBL] [Abstract] [Full Text] [Related]
6. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract] [Full Text] [Related]
7. Synthesis and anti-tumor activity evaluation of 1H-pyrrolo[2,3-b]pyridine-2-carboxamide derivatives with phenyl sulfonamide groups as potent RSK2 inhibitors.
Zhang X; Zheng G; Gao S; Zhou F; Pan T; Shi Q; Li J; Zhang X; Huang Z; Quan X
Chem Biol Drug Des; 2024 Jan; 103(1):e14376. PubMed ID: 37852922
[TBL] [Abstract] [Full Text] [Related]
8. Cullin-associated and neddylation-dissociated 1 regulate reprogramming of lipid metabolism through SKP1-Cullin-1-F-box
Zhang H; Xia P; Yang Z; Liu J; Zhu Y; Huang Z; Zhang Z; Yuan Y
Clin Transl Med; 2023 Oct; 13(10):e1443. PubMed ID: 37837399
[TBL] [Abstract] [Full Text] [Related]
9. Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with breast cancer.
Xiong D; Yang J; Li D; Wang J
Cardiovasc Toxicol; 2023 Oct; 23(9-10):329-348. PubMed ID: 37684436
[TBL] [Abstract] [Full Text] [Related]
10. Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay.
Shamis SA; Savioli F; Ammar A; Al-Badran SS; Hatthakarnkul P; Leslie H; Mallon EE; Jamieson NB; McMillan DC; Edwards J
Histol Histopathol; 2024 Feb; 39(2):177-200. PubMed ID: 37681672
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic Impact of Tumor-Infiltrating Lymphocytes, Tertiary Lymphoid Structures, and Neutrophil-to-Lymphocyte Ratio in Pulmonary Metastases from Uterine Leiomyosarcoma.
Matsuda N; Yamamoto H; Habu T; Iwata K; Matsubara K; Tanaka S; Hashimoto K; Shien K; Suzawa K; Miyoshi K; Toji T; Okazaki M; Sugimoto S; Takahashi K; Toyooka S
Ann Surg Oncol; 2023 Dec; 30(13):8727-8734. PubMed ID: 37658268
[TBL] [Abstract] [Full Text] [Related]
12. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA HOTAIR as a ceRNA is related to breast cancer risk and prognosis.
Qian L; Li L; Li Y; Li S; Zhang B; Zhu Y; Yang B
Breast Cancer Res Treat; 2023 Aug; 200(3):375-390. PubMed ID: 37294527
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathologic Features and Immune Cell Subtypes Analysis of Tumor-infiltrating Lymphocytes Rich Invasive breast Carcinoma of No Special Type.
Zhao Y; Huang T; Jin X; Gong XM; Lu YZ
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):354-362. PubMed ID: 37278279
[TBL] [Abstract] [Full Text] [Related]
15. Aberrant APOBEC3B Expression in breast cancer Is Linked to Proliferation and Cell Cycle Phase.
Roelofs PA; Timmermans MAM; Stefanovska B; den Boestert MA; van den Borne AWM; Balcioglu HE; Trapman AM; Harris RS; Martens JWM; Span PN
Cells; 2023 Apr; 12(8):. PubMed ID: 37190094
[TBL] [Abstract] [Full Text] [Related]
16. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract] [Full Text] [Related]
17. COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer.
Yan Y; Liang Q; Liu Y; Zhou S; Xu Z
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36877531
[TBL] [Abstract] [Full Text] [Related]
18. Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series.
Wu W; Ren K; Li N; Luo Q; Zhou H; Hai T; Zou L
Ann Hematol; 2023 Apr; 102(4):829-839. PubMed ID: 36729147
[TBL] [Abstract] [Full Text] [Related]
19. Comparison of the prognostic value of stromal tumor-infiltrating lymphocytes and CD3 + T cells between schistosomal and non-schistosomal colorectal cancer.
Wang W; Zhang Y; Liu J; Jing H; Lu K; Wang L; Zhu T; Xu Y; Bu D; Cheng M; Liu J; Shen W; Yao J; Huang S
World J Surg Oncol; 2023 Feb; 21(1):31. PubMed ID: 36726115
[TBL] [Abstract] [Full Text] [Related]
20. The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development.
Aljohani AI; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2023 Apr; 198(3):423-435. PubMed ID: 36418517
[TBL] [Abstract] [Full Text] [Related]
[Next]
